EUVIMEDEUVIMED entdecken
Multizentrische Studie

Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study

Genevieve M Crane iD, Julia T Geyer iD, Beenu Thakral, Sa A Wang, Geoffrey D Wool, Ke David Li, Adam R Davis, Leonardo Boiocchi, David Bosler, Carlos E Bueso-Ramos, Daniel A Arber, Tracy I George und 5 weitere

American Journal of Clinical Pathology · 2024

DOI: 10.1093/ajcp/aqae033 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Clinical Pathology, 2024. Verfasst von Genevieve M Crane und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, US. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Mutation, Janus Kinase 2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Myeloproliferative neoplasm, unclassifiable (MPN-U, revised to MPN, not otherwise specified in the fifth edition of the World Health Organization classification) is a heterogeneous category of primary marrow disorders with clinical, morphologic, and/or molecular features that preclude classification as a more specific MPN subtype due to stage at diagnosis, overlapping features between MPN subtypes, or the presence of coexisting disorders. Compared with other MPN subtypes, the contribution of the mutational landscape in MPN-U in conjunction with other clinical and morphologic biomarkers to prognosis has been less well investigated.

Methods

We performed a multicenter, retrospective study of MPN-U (94 cases) to better define the clinicopathologic features, genetic landscape, and clinical outcomes, including subgroups of early-stage, advanced-stage, and coexisting disorders. The Dynamic International Prognostic Scoring System (DIPSS) plus scoring system was applied to assess its relevance to MPN-U prognosis.

Results

Multivariate analysis demonstrated bone marrow blast count and DIPSS plus score as statistically significant in predicting overall survival. Univariate analysis identified additional potential poor prognostic markers, including abnormal karyotype and absence of JAK2 mutation. Secondary mutations were frequent in the subset analyzed by next-generation sequencing (26/37 cases, 70.3%) with a borderline association between high molecular risk mutations and overall survival.

Conclusions

This study, as one of the largest of MPN-U studies incorporating both clinicopathologic and molecular data, moves toward identification of biomarkers that better predict prognosis in this heterogeneous category.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloproliferative DisordersMutationJanus Kinase 2HumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultPrognosisAged, 80 and overBone MarrowYoung AdultAdolescent

Stichwörter der Autor:innen

JAK2 mutationDynamic International Prognostic Scoring System (DIPSS) plushigh molecular risk mutationsmyeloproliferative neoplasmnot otherwise specifiedsplanchnic vein thrombosisunclassifiable

Substanzen

Janus Kinase 2JAK2 protein, human

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, US.
  • Department of Pathology, Weill Cornell Medicine, New York, NY, US.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, US.
  • Department of Pathology, University of Chicago, Chicago, IL, US.
  • Department of Pathology, University of Utah, Salt Lake City, UT, US.
  • Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, US.

ORCID-Profile: Genevieve M Crane, Julia T Geyer, Eric D Hsi

Zitieren

APA

Crane, G. M., Geyer, J. T., Thakral, B., Wang, S. A., Wool, G. D., Li, K. D., Davis, A. R., Boiocchi, L., Bosler, D., Bueso-Ramos, C. E., Arber, D. A., George, T. I., Bagg, A., Hasserjian, R. P., Orazi, A., Hsi, E. D., & Rogers, H. J. (2024). Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae033

Vancouver

Crane GM, Geyer JT, Thakral B, Wang SA, Wool GD, Li KD, et al. Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study. American Journal of Clinical Pathology. 2024. doi:10.1093/ajcp/aqae033

BibTeX
@article{Crane2024,
  author = {Crane, Genevieve M and Geyer, Julia T and Thakral, Beenu and Wang, Sa A and Wool, Geoffrey D and Li, Ke David and Davis, Adam R and Boiocchi, Leonardo and Bosler, David and Bueso-Ramos, Carlos E and Arber, Daniel A and George, Tracy I and Bagg, Adam and Hasserjian, Robert P and Orazi, Attilio and Hsi, Eric D and Rogers, Heesun J},
  title = {Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study},
  journal = {American Journal of Clinical Pathology},
  year = {2024},
  doi = {10.1093/ajcp/aqae033}
}
Kostenlos starten →